Anti-neoplastic properties of hydralazine in prostate cancer
Open Access
- 17 April 2014
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 5 (15) , 5950-5964
Abstract
Anti-neoplastic properties of hydralazine in prostate cancerKeywords
This publication has 40 references indexed in Scilit:
- The future of epigenetic therapy in solid tumours—lessons from the pastNature Reviews Clinical Oncology, 2013
- Hormonal Therapy Promotes Hormone-Resistant Phenotype by Increasing DNMT Activity and Expression in Prostate Cancer ModelsEndocrinology, 2011
- Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancerApoptosis, 2010
- New Developments in the Medical Management of Prostate CancerMayo Clinic Proceedings, 2010
- The DNA-damage response in human biology and diseaseNature, 2009
- Minireview: Epigenetic Alterations in Human Prostate CancersEndocrinology, 2009
- Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen‐independent prostate cancer cellsThe Prostate, 2008
- Epidermal growth factor receptor activation in prostate cancer by three novel missense mutationsOncogene, 2008
- The role of Src in prostate cancerAnnals of Oncology, 2007
- Hydralazine may induce autoimmunity by inhibiting extracellular signal–regulated kinase pathway signalingArthritis & Rheumatism, 2003